Research Analysts Offer Predictions for UTHR FY2027 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at HC Wainwright dropped their FY2027 EPS estimates for United Therapeutics in a note issued to investors on Friday, September 5th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $28.37 for the year, down from their previous forecast of $28.77. HC Wainwright has a “Buy” rating and a $500.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the business earned $5.85 earnings per share.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, August 14th. Oppenheimer increased their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Jefferies Financial Group increased their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $429.62.

United Therapeutics Stock Up 5.3%

Shares of NASDAQ UTHR opened at $400.52 on Monday. The firm has a 50-day simple moving average of $307.69 and a 200-day simple moving average of $305.37. The stock has a market capitalization of $18.07 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 6.11 and a beta of 0.62. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $436.95.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of United Therapeutics during the first quarter valued at about $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC increased its position in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after acquiring an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after acquiring an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter valued at about $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Christopher Causey sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $423.21, for a total transaction of $1,269,630.00. Following the completion of the sale, the director directly owned 4,865 shares in the company, valued at approximately $2,058,916.65. This trade represents a 38.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 106,181 shares of company stock valued at $35,537,239 in the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.